CDMO
Avid Bioservices, Inc.·Healthcare
12.49
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $5.9052W H: $12.51
CDMO NEWS
prnewswire.com
5d ago
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, today announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization.
prnewswire.com
Apr 1
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025.
prnewswire.com
Mar 30
Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
Financial HighlightsRevenue reached RMB1,729.4 millionGross profit amounted to RMB655.6 millionGross profit margin recorded 37.9%, a YOY increase of 3.3 pp Net profit recorded RMB269.3 million, a YOY increase 21.3%Adjusted non-IFRS net profit recorded RMB335.3 million, a YOY increase of nearly 6.6% SHANGHAI, March 30, 2026 /PRNewswire/ -- On March 30, 2026, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue amounted to RMB1,729.4 million during the Reporting Period, with gross profit of RMB655.6 million. The Group's gross profit margin was 37.9%, representing an increase of 3.3 percentage points compared with the same period last year, mainly attributable to the optimization and adjustment of Langhua Pharmaceutical's business mix, improved operational efficiency of the CRO business.
businesswire.com
Mar 30
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote
INCHEON, South Korea--(BUSINESS WIRE)--Samsung Biologics Labor Union secured a strike mandate, warning that governance failures and rigid management pose CDMO supply chain risks.
prnewswire.com
Mar 30
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management".
prnewswire.com
Mar 26
Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards
Reinforcing long-term commitment to embedding sustainability across operations and partnerships Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide INCHEON, South Korea, March 26, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), received recognition at the 2026 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect. The company was awarded the Sustainability Leadership Award, a jury-selected distinction recognizing efforts to advance sustainable practices across its operations and value chain.
